SCHEMBL13168043

SCHEMBL13168043

CCOC(=O)c1cc(OC)c(OCCCN2CCCCC2)cc1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
KDM4E B2RXH2 1/20 0.56
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 1/20 0.49
ACHE P22303 2/20 0.48
BCHE P06276 1/20 0.48
HTR4 Q13639 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
HTR3A P46098 1/20 0.48
CACNA1F O60840 3/20 0.48
CACNA1D Q01668 3/20 0.48
CACNA1S Q13698 3/20 0.48
CACNA1C Q13936 3/20 0.48
HRH3 Q9Y5N1 2/20 0.48
KCNH2 Q12809 1/20 0.47
NMT2 O60551 1/20 0.46
NMT1 P30419 1/20 0.46
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3709691 0.90 ALDH1A1 (0.57) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL3527664 0.90 ALDH1A1 (0.57) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL10102461 0.90 ALDH1A1 (0.58) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL19260738 0.90 ALDH1A1 (0.54) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL7838137 0.86 KDM4E (0.61) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL2927309 0.85 ALDH1A1 (0.54) ALDH1A1KDM4EMEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL2920128 0.85 KDM4E (0.60) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL6336768 0.83 HTR4 (0.62) ALDH1A1MEN1KMT2AACHEBCHE
SCHEMBL13168044 0.83 PKM (0.50) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL17375521 0.82 SIRT6 (0.51) ALDH1A1KDM4ELMNACYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536184-B2 Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-09-17 US disclosed
US-20100240893-A1 NITROGENOUS HETEROCYCLIC COMPOUNDS AND PROCESS FOR MAKING NITROGENOUS HETEROCYCLIC COMPOUNDS AND INTERMEDIATES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-09-23 US disclosed
US-7709640-B2 Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240893-A1 NITROGENOUS HETEROCYCLIC COMPOUNDS AND PROCESS FOR MAKING NITROGENOUS HETEROCYCLIC COMPOUNDS AND INTERMEDIATES THEREOF NME1, NME2, TNNI3K ALDH1A1 2813/4885KDM4E 1061/4885MEN1 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.